Janux Therapeutics (JANX) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to 352.51%.
- Janux Therapeutics' EBIT Margin rose 78119500.0% to 352.51% in Q3 2025 from the same period last year, while for Sep 2025 it was 1442.88%, marking a year-over-year decrease of 7841200.0%. This contributed to the annual value of 933.58% for FY2024, which is 307100.0% down from last year.
- According to the latest figures from Q3 2025, Janux Therapeutics' EBIT Margin is 352.51%, which was up 78119500.0% from 8164.46% recorded in Q3 2024.
- Over the past 5 years, Janux Therapeutics' EBIT Margin peaked at 155.36% during Q2 2024, and registered a low of 8164.46% during Q3 2024.
- In the last 5 years, Janux Therapeutics' EBIT Margin had a median value of 843.51% in 2021 and averaged 1338.23%.
- In the last 5 years, Janux Therapeutics' EBIT Margin plummeted by -75362200bps in 2024 and then skyrocketed by 78119500bps in 2025.
- Janux Therapeutics' EBIT Margin (Quarter) stood at 834.78% in 2021, then grew by 23bps to 642.04% in 2022, then decreased by -2bps to 655.71% in 2023, then crashed by -1145bps to 8164.46% in 2024, then skyrocketed by 96bps to 352.51% in 2025.
- Its last three reported values are 352.51% in Q3 2025, 8164.46% for Q3 2024, and 155.36% during Q2 2024.